Nexus Pharmaceuticals gets FDA nod for generic Compazine
Nexus has received clearance from the Food and Drug Administration for its generic Compazine (prochlorperazine edisylate) injection in a 10 mg/2 mL vial.
The product is the generic of Heritage Pharmaceuticals’ Compazine.
Prochlorperazine edisylate injection is indicated to control severe nausea and vomiting. It also is indicated for the treatment of schizophrenia.
“The launch further expands our generic injectable portfolio, but more importantly, it shows our commitment to meeting the increased market demand of generic injectables and mitigate the risk of future drug shortages,” Nexus chief commercial officer Omair Ahmed said.
Nexus’ prochlorperazine edisylate injection is available in cartons of 10 vials.
The product is the generic of Heritage Pharmaceuticals’ Compazine.
Prochlorperazine edisylate injection is indicated to control severe nausea and vomiting. It also is indicated for the treatment of schizophrenia.
“The launch further expands our generic injectable portfolio, but more importantly, it shows our commitment to meeting the increased market demand of generic injectables and mitigate the risk of future drug shortages,” Nexus chief commercial officer Omair Ahmed said.
Nexus’ prochlorperazine edisylate injection is available in cartons of 10 vials.